An adamantane actoprotector (Ladasten in Russia) studied for work capacity under extreme conditions, later caught by WADA after the 1996 Atlanta positives.
Actoprotector · Soviet military-pharmacology line · N-(2-adamantyl)-N-(p-bromophenyl)amine
2D structure from PubChem open data (CID 4660557). Archive label only.
Key takeaways
Bromantane is the adamantane face of the actoprotector line (N-(2-adamantyl)-N-(p-bromophenyl)amine; Ladasten in Russia).
Mapped papers cover endurance and behavioural load tests, immunomodulatory / cytokine work under ladasten, and gene-expression / histone-acetylation mechanism titles.
Pharmacology and sports-medicine literature mix Russian lab series with international doping-control history after the 1996 Atlanta positives. that sports-control trail is part of the public record this archive maps.
What it is
Bromantane is the adamantane face of the actoprotector line: N-(2-adamantyl)-N-(p-bromophenyl)amine, marketed in Russia as Ladasten.
Soviet claims framed an “activation without tachycardia” profile; WADA’s ban after 1996 Atlanta positives is part of the public paper trail, not a clinical grade.
We feature it beside bemitil because the archive repeatedly pairs the two under heat-plus-load stress, while their proposed mechanisms diverge.
What the literature describes
Themed chapters drawn only from papers already mapped on this dossier. Archive map. No medical advice.
Endurance and behavioural load tests
Swim and stress-test papers report longer endurance under bromantane versus control in animal models of physical load.
Pharmacology and sports-medicine literature mix Russian lab series with international doping-control and analogue papers. The endurance and anxiolytic-activation story is densest in Russian sources; the WADA / Atlanta trail is a separate public-record layer this archive also maps.
Open limits
How should endurance and activation stories concentrated in Russian lab series be read against later doping-control analytics?
What does high tissue penetration imply for long-term safety questions the archive has not settled?
Where do reference-compound screens end and single-agent mechanism papers begin?
Russian full-text papers
CyberLeninka full text from the archive corpus.
2026Взаимодействие гибридной молекулы ADK-1113 с σ₁-, NMDAи AMPA-рецепторами: исследование методами докинга и мCyberLeninka
2026Разработка самоэмульгирующейся системы доставки N-(адамант-2-ил)-N-(пара-бромфенил)амина (адамантилбромфениCyberLeninka
2025Исследование антипаркинсонической активности комбинации ладастена с фабомотизолом на модели паракват-индуциCyberLeninka
2024АНТИГИПОКСИЧЕСКИЕ ЭФФЕКТЫ 2-ЭТИЛТИОБЕНЗИМИДАЗОЛА И КОМПЛЕКСА СОЛЕЙ ЯНТАРНОЙ КИСЛОТЫ У ПРЕДВАРИТЕЛЬНО ТРЕНИРCyberLeninka
2024Оценка психотропной активности новых структурных аналогов бромантана. N-(камфан-2-ил)анилинов. в тестах iCyberLeninka
2023Применение психоактивных веществ в боевых условиях армиями зарубежных странCyberLeninka
2022ВЛИЯНИЕ СЕЛАНКА НА МОРФИН-ИНДУЦИРОВАННУЮ АНАЛЬГЕЗИЮ В ОПЫТАХ IN VIVOCyberLeninka
2022ВЛИЯНИЕ ЭКСТРАКТА СУХОГО SERRATULA CENTAUROIDES L. (ASTERACEAE) НА ПРОЦЕССЫ РЕПРОДУКЦИИ КРЫС-САМЦОВCyberLeninka
2022НОВЫЕ ВОЗМОЖНОСТИ В ТЕРАПИИ АСТЕНИЧЕСКИХ СИМПТОМОВ ПОСЛЕ ПЕРЕНЕСЕННОЙ НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИИCyberLeninka
2022СРАВНИТЕЛЬНОЕ ИЗУЧЕНИЕ ВЛИЯНИЯ ПРОИЗВОДНЫХ АДАМАНТАНА НА ПОВЕДЕНИЕ МЫШЕЙ CD-1 C РАЗНЫМ ФЕНОТИПОМ УСТОЙЧИВОСCyberLeninka
2021Астенический синдром у детей и подростков: выбор терапииCyberLeninka
12 from corpus · more on Papers
Also on PubMed
2014Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state. doi:10.1007/s10517-014-2343-1PubMed
2012Mechanisms of action of ladasten: activation of gene expression for neurotrophins and mitogen-activated kinases. doi:10.1007/s10517-012-1516-zPubMed
2012[Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types].PubMed
2012[Effect of ladasten on antenatal and postnatal development].PubMed
2011[Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients].PubMed
2011Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome. doi:10.1007/s10517-011-1453-2PubMed
2011Time course of histone deacetylase 1 and acetylated H3 and H4 histones in the brain of rats treated with ladasten. doi:10.1007/s10517-011-1201-7PubMed
2011[Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice].PubMed
Why do classical stimulants underperform placebo under heat load in the military-pharmacology literature that also discusses bromantane combinations?
How should Russian scheduling of Ladasten be read against the absence of international controlled-substance listing?
What does high tissue penetration imply for long-term safety questions the archive has not settled?
Reviewed against the archive corpora on 2026-09-19. Source-grounded. No clinical claims. Archive / history / research only. No medical advice. No dosing, synthesis, sourcing, or health claims.
